Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Compass Therapeutics Inc Market Cap
Based on ratings from 0 stock analysts, the Compass Therapeutics Inc stock price is expected to increase by 356.02% in 12 months. This is calculated by using the average 12-month stock price forecast for Compass Therapeutics Inc. The lowest target is $5 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.
CMPX is a stock in Health Care which has been forecasted to be worth $7.57 as an average. On the higher end, the forecast price is $10 USD by Joseph Pantginis from HC Wainwright & Co. and on the lower end CMPX is forecasted to be $5 by Aydin Huseynov from Ladenburg Thalmann.
These are the latest 20 analyst ratings of CMPX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Aydin Huseynov Ladenburg Thalmann | Buy | $5 | Upgrade | Sep 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 12, 2024 |
| Robert Driscoll Wedbush | Outperform | $8 | Reiterates | Aug 7, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 6, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Jun 3, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | May 16, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | May 14, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Apr 16, 2024 |
| Robert Driscoll Wedbush | Outperform | $8 | Reiterates | Mar 22, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Maintains | Mar 21, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 3, 2023 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Reiterates | Mar 16, 2023 |
| Maury Raycroft Jefferies | Buy | $8 | Initiates | Jan 31, 2023 |
| Stephen Willey Stifel | Buy | $9 | Initiates | Jan 27, 2023 |
| Michael King EF Hutton | Buy | $10.3 | Initiates | Dec 16, 2022 |
| Dane Leone Raymond James | Outperform | $8 | Maintains | Nov 10, 2022 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $10 | Maintains | Nov 3, 2022 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $12 | Assumes | May 23, 2022 |
| Andrew Berens SVB Leerink | Outperform | $11 | Maintains | May 5, 2022 |
Ladenburg Thalmann | Buy | Initiates | Mar 15, 2022 |
When did it IPO
N/A
Staff Count
32
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Thomas J. Schuetz M.D., Ph.D.
Market Cap
$234.6M
In 2023, CMPX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CMPX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024.
Wed, 07 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York City, New York on Tuesday, August 13, 2024, at 11 AM ET.
Wed, 10 Jul 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Thu, 20 Jun 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Compass Therapeutics is an oncology-focused biotech developing novel immunotherapies for solid tumors, with a focus on gastrointestinal cancers. Their most advanced candidate, CTX-009, targets DLL4 and VEGF in biliary tract cancer, showing promising early response rates. Despite financial stability and potential game-changing catalysts, risks include toxicity concerns and comparator arm issues in their phase 3 trial.
Thu, 30 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.
Tue, 28 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
